Open AccessEmerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia
Author(s) -
Sébastien Gallien,
Constance Delaugerre,
Isabelle Charreau,
Joséphine Braun,
Thomas Boulet,
Aurélie Barrail-Tran,
Nathalie De Castro,
JeanMichel Molina,
Daniel R. Kuritzkes
Publication year - 2011
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e3283445834
Subject(s) - raltegravir , viremia , integrase inhibitor , integrase , virology , elvitegravir , viral load , medicine , genotyping , genotype , biology , virus , genetics , human immunodeficiency virus (hiv) , antiretroviral therapy , gene
The emergence of integrase strand-transfer inhibitor (INSTI) resistance-associated mutations was examined in patients with low-level viremia after switching from enfuvirtide to raltegravir in the ANRS 138-Easier trial.